1260181-07-4

Basic information

• Product Name: 3-(5-fluoro-2-(trifluoromethyl)phenyl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione
• Synonyms: 3-(5-fluoro-2-(trifluoromethyl)phenyl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione
• CAS NO: 1260181-07-4
• Molecular Weight: 374.294
• Mol File: 1260181-07-4.mol

Chemical Properties

• CAS DataBase Reference: 3-(5-fluoro-2-(trifluoromethyl)phenyl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(5-fluoro-2-(trifluoromethyl)phenyl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione(1260181-07-4)
• EPA Substance Registry System: 3-(5-fluoro-2-(trifluoromethyl)phenyl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione(1260181-07-4)

Safety Data

• Hazardous Substances Data: 1260181-07-4(Hazardous Substances Data)

Upstream product

• 18372-22-0 2-(3-indolyl)oxoacetic acid methyl ester 
• 1260181-08-5 2-(5-fluoro-2-(trifluoromethyl)phenyl)acetamide 

Downstream Products

• 1260181-13-2 3-(1H-indol-3-yl)-4-(5-morpholin-4-yl-2-trifluoromethylphenyl)pyrrole-2,5-dione 
• 1260181-10-9 3-(1H-indol-3-yl)-4-(5-piperazin-1-yl-2-trifluoromethylphenyl)pyrrole-2,5-dione 
• 1260181-12-1 4-{3-[4-(1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-4-trifluoromethylphenyl}piperazine-1-carbaldehyde 
• 1260181-14-3 3-{5-[4-(2-hydroxy-2-methylpropionyl)piperazin-1-yl]-2-trifluoromethylphenyl}-4-(1H-indol-3-yl)pyrrole-2,5-dione 
• 1260181-11-0 3-(5-dimethylamino-2-trifluoromethylphenyl)-4-(1H-indol-3-yl)pyrrole-2,5-dione 

Relevant articles and documents

Identification of a potent janus kinase 3 inhibitor with high selectivity within the janus kinase family

We describe a synthetic approach toward the rapid modification of phenyl-indolyl maleimides and the discovery of potent Jak3 inhibitor 1 with high selectivity within the Jak kinase family. We provide a rationale for this unprecedented selectivity based on

Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor

JAK family kinases are important mediators of immune cell signaling and Janus Kinase 3 (JAK3) has long been indicated as a potential target for autoimmune disorders. Intensive efforts to develop highly selective JAK3 inhibitors have been underway for many years. However, because of JAK3's strong binding preference to adenosine 5′-triphosphate (ATP), a number of inhibitors exhibit large gaps between enzymatic and cellular potency, which hampers efforts to dissect the roles of JAK3 in cellular settings. Using a targeted covalent inhibitor approach, we discovered compound 32, which overcame ATP competition (1 mM) in the enzymatic assay, and demonstrated significantly improved inhibitory activity for JAK3-dependent signaling in mouse CTLL-2 and human peripheral blood mononuclear cells. Compound 32 also exhibited high selectivity within the JAK family and good pharmacokinetic properties. Thus, it may serve as a highly valuable tool molecule to study the overlapping roles of JAK family kinases in complex biological settings. Our study also suggested that for covalent kinase inhibitors, especially those targeting kinases with low Km ATP values, the reversible interactions between molecules and proteins should be carefully optimized to improve the overall potency.

JAK3 selective inhibitor

The invention discloses a JAK3 selective inhibitor, and relates to a compound represented by formula I/II, or a pharmaceutically acceptable salt thereof. In formula I, Rh, Rg, Rf, m, Re, Rd, Ra, Rb and Rc are as defined in the specification, formula II. The invention also relates to a pharmaceutical composition containing the compound shown in the formula I/II or the pharmaceutically acceptable salt thereof, and applications of the pharmaceutical composition in preparation of drugs for treating inflammation such as rheumatoid arthritis.